About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Safe, And Other Four-Letter Words | Main | Chemistry Geekery »

November 23, 2004

I Don't See How This Qualifies As Bliss

Email This Entry

Posted by Derek

No blogging window for today - there will be a post tomorrow, and then I'll take a break until next Monday. For now, I recommend this post over at Uncertain Principles. Its implications for public discussions of drug discovery and safety should be pretty clear (as will the title of this post, for that matter!)

Which reminds me - I've been rebuilding the blogroll over there on the left, and I encourage you to check out any that you're not familiar with. More sites are coming, including a lot of the medical/pharma links that I had before. Suggestions welcome.

Comments (1) + TrackBacks (0) | Category:


1. JSinger on November 28, 2004 3:51 PM writes...

My impression is that there's a distinction between "skeptics", who are primarily concerned with obliterating views they consider irrational, and scientists. There is an overlap between the two groups, but most "skeptics" aren't research scientists and most scientists have little interest in a mean-spirited culture clash. Speaking for myself, years in the lab have made me far less likely to get on a soapbox about how Science and Reason make me Right and others Wrong.

The reality is that people have a sort of cognitive dissonance about things they consider fun (ghosts, astrology) or sacred (God's role in creation). I would far rather see journalists grasp basic notions of statistical significance and "educated" people understand what a half-life is than fight with people who are uncomfortable with explicitly questioning their received belief. I'd also rather see science perceived as a thing of joy and wonder (yeah, I know, I went to grad school too) than as the theology of confrontational, elitist, humorless snobs.

Permalink to Comment


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry